- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07943000
Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) Activity (TRACer)
This study will examine how low doses of ethacrynic acid affect substances in the blood involved in protecting cells from damage. These substances include glutathione and an enzyme called glutathione S-transferase. The findings may help researchers plan future cancer studies.
Ethacrynic acid is an approved prescription medicine used to treat fluid buildup. Its use in this study to change these blood markers in healthy adults is experimental.
Up to 40 healthy adults will participate. The first group will receive a 25 mg oral dose at each of two visits approximately one week apart. If results meet the study criteria, a second group will receive 12.5 mg at each visit.
Participants will provide blood samples before and approximately 90 minutes after each dose. Study staff will ask about symptoms during the visits and during a final telephone call approximately one week after the second dose. Participation will last approximately two weeks.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Glutathione (GSH) and glutathione S-transferases (GSTs) contribute to cellular protection against oxidative stress and the detoxification of electrophilic compounds. In cancer cells, increased activity of these systems may contribute to resistance to anticancer therapies. Ethacrynic acid, an approved loop diuretic, can inhibit GST activity and react with GSH to form conjugates, potentially reducing cellular GSH availability. Whether low oral doses produce measurable pharmacodynamic effects in healthy adults remains uncertain.
TRACer will investigate these biological effects in healthy volunteers to reduce confounding from malignancy, prior cancer treatment, organ dysfunction, and concurrent prescription medications. The study uses paired measurements before and after drug administration, allowing each participant to serve as their own control. Repeating administration approximately one week later will help characterize the consistency of the pharmacodynamic response. Comparison of pre-dose measurements across visits will also provide information about whether changes persist between administrations.
The sequential cohort design evaluates the higher dose first. Enrollment into the lower-dose cohort will occur only if the initial cohort meets the protocol-specified criterion for biological activity. This approach is intended to determine whether target engagement can be demonstrated at doses below those commonly used to produce diuresis.
Peripheral blood mononuclear cells provide accessible material for assessing GST activity. Measurements of total GSH in plasma and erythrocytes provide complementary information about glutathione pools in different blood compartments. Coded specimens will undergo research laboratory analysis at the University of Vermont. These assays will not guide clinical care, and individual research results will not be returned to participants.
The study is intended to inform the design of subsequent investigations of ethacrynic acid as a potential adjunct to cancer therapy. It does not evaluate antitumor activity, and no direct clinical benefit to participants is anticipated.
Studietyp
Inskrivning (Beräknad)
Fas
- Tidig fas 1
Kontakter och platser
Studiekontakt
- Namn: Randall Holcombe, MD, MBA
- Telefonnummer: 802-656-2207
- E-post: Randall.holcombe@med.uvm.edu
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Healthy volunteer without acute or chronic illness.
- Age 18 years or older.
- Willing and able to provide informed consent.
Exclusion Criteria:
- Ongoing use of any prescription medication.
- Known hypersensitivity to ethacrynic acid.
- Known renal or hepatic impairment.
- Current pregnancy or breastfeeding.
- Current tinnitus, hearing impairment, or other significant hearing disorder.
- Baseline systolic blood pressure of 100 mm Hg or less.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Ethacrynic Acid 25 mg
Approximately 20 participants will receive ethacrynic acid 25 mg orally at each of two dosing visits separated by one week ±1 day. |
Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.
Andra namn:
|
|
Experimentell: Ethacrynic Acid 12.5 mg
If the first cohort meets the protocol-specified biological activity criterion, approximately 20 additional participants will receive ethacrynic acid 12.5 mg orally at each of two dosing visits separated by one week ±1 day. |
Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Peripheral Blood Mononuclear Cell GST Activity
Tidsram: Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later
|
Change in glutathione S-transferase activity from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit. |
Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Plasma Total Glutathione
Tidsram: Before dosing and 90 ±15 minutes after dosing at both dosing visits
|
Change in plasma total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit. |
Before dosing and 90 ±15 minutes after dosing at both dosing visits
|
|
Change in Erythrocyte Total Glutathione
Tidsram: Before dosing and 90 ±15 minutes after dosing at both dosing visits
|
Change in erythrocyte total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit. |
Before dosing and 90 ±15 minutes after dosing at both dosing visits
|
|
Number of Participants With Adverse Events
Tidsram: From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks
|
Number of participants experiencing adverse events, summarized by event type, severity, and relatedness. Severity will be graded using the protocol's CTCAE criteria. |
From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- UVMCC2609
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .